204 related articles for article (PubMed ID: 32853771)
1. Nucleophosmin, a multifunctional nucleolar organizer with a role in DNA repair.
López DJ; Rodríguez JA; Bañuelos S
Biochim Biophys Acta Proteins Proteom; 2020 Dec; 1868(12):140532. PubMed ID: 32853771
[TBL] [Abstract][Full Text] [Related]
2. Elucidation of motifs in ribosomal protein S9 that mediate its nucleolar localization and binding to NPM1/nucleophosmin.
Lindström MS
PLoS One; 2012; 7(12):e52476. PubMed ID: 23285058
[TBL] [Abstract][Full Text] [Related]
3. When the good go bad: Mutant NPM1 in acute myeloid leukemia.
Kunchala P; Kuravi S; Jensen R; McGuirk J; Balusu R
Blood Rev; 2018 May; 32(3):167-183. PubMed ID: 29157973
[TBL] [Abstract][Full Text] [Related]
4. Functional regulation of the apurinic/apyrimidinic endonuclease 1 by nucleophosmin: impact on tumor biology.
Vascotto C; Lirussi L; Poletto M; Tiribelli M; Damiani D; Fabbro D; Damante G; Demple B; Colombo E; Tell G
Oncogene; 2014 May; 33(22):2876-87. PubMed ID: 23831574
[TBL] [Abstract][Full Text] [Related]
5. Self-interaction of NPM1 modulates multiple mechanisms of liquid-liquid phase separation.
Mitrea DM; Cika JA; Stanley CB; Nourse A; Onuchic PL; Banerjee PR; Phillips AH; Park CG; Deniz AA; Kriwacki RW
Nat Commun; 2018 Feb; 9(1):842. PubMed ID: 29483575
[TBL] [Abstract][Full Text] [Related]
6. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications.
Falini B; Bolli N; Liso A; Martelli MP; Mannucci R; Pileri S; Nicoletti I
Leukemia; 2009 Oct; 23(10):1731-43. PubMed ID: 19516275
[TBL] [Abstract][Full Text] [Related]
7. New insights into the biology of acute myeloid leukemia with mutated NPM1.
Brunetti L; Gundry MC; Goodell MA
Int J Hematol; 2019 Aug; 110(2):150-160. PubMed ID: 30632059
[TBL] [Abstract][Full Text] [Related]
8. Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia.
Nabbouh AI; Hleihel RS; Saliba JL; Karam MM; Hamie MH; Wu HJM; Berthier CP; Tawil NM; Bonnet PA; Deleuze-Masquefa C; El Hajj HA
Cancer; 2017 May; 123(9):1662-1673. PubMed ID: 28055106
[TBL] [Abstract][Full Text] [Related]
9. Nucleophosmin interaction with APE1: Insights into DNA repair regulation.
López DJ; de Blas A; Hurtado M; García-Alija M; Mentxaka J; de la Arada I; Urbaneja MA; Alonso-Mariño M; Bañuelos S
DNA Repair (Amst); 2020 Apr; 88():102809. PubMed ID: 32092641
[TBL] [Abstract][Full Text] [Related]
10. Compositional adaptability in NPM1-SURF6 scaffolding networks enabled by dynamic switching of phase separation mechanisms.
Ferrolino MC; Mitrea DM; Michael JR; Kriwacki RW
Nat Commun; 2018 Nov; 9(1):5064. PubMed ID: 30498217
[TBL] [Abstract][Full Text] [Related]
11. Identification of a novel nucleophosmin-interaction motif in the tumor suppressor p14arf.
Luchinat E; Chiarella S; Franceschini M; Di Matteo A; Brunori M; Banci L; Federici L
FEBS J; 2018 Mar; 285(5):832-847. PubMed ID: 29283500
[TBL] [Abstract][Full Text] [Related]
12. Interactions of the natural product (+)-avrainvillamide with nucleophosmin and exportin-1 Mediate the cellular localization of nucleophosmin and its AML-associated mutants.
Mukherjee H; Chan KP; Andresen V; Hanley ML; Gjertsen BT; Myers AG
ACS Chem Biol; 2015 Mar; 10(3):855-63. PubMed ID: 25531824
[TBL] [Abstract][Full Text] [Related]
13. Structural consequences of nucleophosmin mutations in acute myeloid leukemia.
Grummitt CG; Townsley FM; Johnson CM; Warren AJ; Bycroft M
J Biol Chem; 2008 Aug; 283(34):23326-32. PubMed ID: 18511415
[TBL] [Abstract][Full Text] [Related]
14. Current status and future perspectives in targeted therapy of NPM1-mutated AML.
Ranieri R; Pianigiani G; Sciabolacci S; Perriello VM; Marra A; Cardinali V; Pierangeli S; Milano F; Gionfriddo I; Brunetti L; Martelli MP; Falini B
Leukemia; 2022 Oct; 36(10):2351-2367. PubMed ID: 36008542
[TBL] [Abstract][Full Text] [Related]
15. Nucleophosmin mutations alter its nucleolar localization by impairing G-quadruplex binding at ribosomal DNA.
Chiarella S; De Cola A; Scaglione GL; Carletti E; Graziano V; Barcaroli D; Lo Sterzo C; Di Matteo A; Di Ilio C; Falini B; Arcovito A; De Laurenzi V; Federici L
Nucleic Acids Res; 2013 Mar; 41(5):3228-39. PubMed ID: 23328624
[TBL] [Abstract][Full Text] [Related]
16. Nucleophosmin in leukemia: Consequences of anchor loss.
Brodská B; Šašinková M; Kuželová K
Int J Biochem Cell Biol; 2019 Jun; 111():52-62. PubMed ID: 31009764
[TBL] [Abstract][Full Text] [Related]
17. Acute myeloid leukemia with mutated nucleophosmin (NPM1): any hope for a targeted therapy?
Falini B; Gionfriddo I; Cecchetti F; Ballanti S; Pettirossi V; Martelli MP
Blood Rev; 2011 Nov; 25(6):247-54. PubMed ID: 21724308
[TBL] [Abstract][Full Text] [Related]
18. APE1/Ref-1 interacts with NPM1 within nucleoli and plays a role in the rRNA quality control process.
Vascotto C; Fantini D; Romanello M; Cesaratto L; Deganuto M; Leonardi A; Radicella JP; Kelley MR; D'Ambrosio C; Scaloni A; Quadrifoglio F; Tell G
Mol Cell Biol; 2009 Apr; 29(7):1834-54. PubMed ID: 19188445
[TBL] [Abstract][Full Text] [Related]
19. Nucleophosmin 1: from its pathogenic role to a tantalizing therapeutic target in acute myeloid leukemia.
Shi Y; Xue Y; Wang C; Yu L
Hematology; 2022 Dec; 27(1):609-619. PubMed ID: 35621728
[TBL] [Abstract][Full Text] [Related]
20. Nucleophosmin Plays a Role in Repairing DNA Damage and Is a Target for Cancer Treatment.
Sekhar KR; Freeman ML
Cancer Res; 2023 May; 83(10):1573-1580. PubMed ID: 36877156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
